+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Gene Therapy, RNA-based Therapies), By Service, By End-use, By Application, By Region, And Segment Forecasts, 2024 - 2030

  • PDF Icon

    Report

  • 125 Pages
  • August 2024
  • Region: Global
  • Grand View Research
  • ID: 5893100
Description Jump to:

Nucleic Acid Therapeutics CDMO Market Growth & Trends

The global nucleic acid therapeutics CDMO market size is expected to reach USD 33.86 billion by 2030, registering a CAGR of 14.10% during the forecast period. The market's growth is primarily attributed to factors such as increasing demand for nucleic acid therapeutics, advancements in nucleic acid technologies, and rising FDA approvals of nucleic acid therapeutics, propelling the need for cost-effective contract development and manufacturing services.

Growing investment and interest in gene therapy research and development by biotechnology companies, pharmaceutical firms, and academic institutions are driving the demand for CDMO services. CDMOs have played a crucial role in gene therapy manufacturing. For instance, Catalent has taken on the primary role as the commercial manufacturing partner for Sarepta Therapeutics in their efforts to advance gene therapy solutions.

The success of mRNA vaccines in responding to the COVID-19 pandemic has showcased the potential of nucleic acid therapeutics, stimulating further research and investment in this field. For instance, in March 2022, Sanofi announced that it plans to allocate USD 1.02 billion (935 million euros) for the development of messenger RNA vaccines in France over the coming years. Sanofi intends to allocate this investment until 2026 as a part of a 2-billion-euro global investment initiative unveiled in June 2021. This initiative is designed to expedite the company's mRNA strategy. Such increased funding scenarios drive market growth.

Furthermore, increasing incidences of CDMO acquisitions and partnerships are expected to accelerate the market growth for nucleic acid therapeutics CDMO in the coming years. For instance, in May 2022, eureKARE initiated a merger worth USD 160.98 million (€150 million) to create a cell & gene therapy contract development and manufacturing organization (CDMO).

The company has established eureKING, a Special Purpose Acquisition Company (SPAC), with the aim of merging three European Contract Development and Manufacturing Organizations (CDMOs) into a unified entity. In another instance, in April 2022, Fujifilm broadened its Advanced Therapies Contract Development and Manufacturing Organization (CDMO) portfolio by acquiring a specialized cell therapy manufacturing facility from Atara Biotherapeutics, Inc. located in California. Such initiatives are expected to boost market growth.

Nucleic Acid Therapeutics CDMO Market Report Highlights

  • The RNA-based therapies segment held the largest revenue share in 2023. RNA-based therapies, mainly mRNA, offer versatility in addressing various diseases. They can be designed to produce a variety of therapeutic proteins, making them applicable to diverse therapeutic areas.
  • The gene therapy segment is expected to show significant market growth in the coming years. This is attributed to the clinical success of gene therapies, which have helped in expanding indications of gene therapies.
  • In 2023, the manufacturing services segment dominated the market, accounting for over 38.37% of the total revenue share. Key factors contributing to segment growth include complex manufacturing processes, scale-up & production challenges, and cost efficiency.
  • The biotechnology companies held a major revenue share of over 58% in 2023 due to substantial investments in the research and development of innovative therapies.
  • North America held the largest revenue share of 40.24% in the nucleic acid therapeutic CDMO market in 2023. Substantial investments and funding support, strong academic and research institutions, and global expansion of CDMOs drive regional growth.

Why should you buy this report?

  • Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players worldwide.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listing for you to stay ahead of the curve
  • COVID-19's impact and how to sustain in these fast-evolving markets

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Regional Scope
1.1.2. Estimates and Forecast Timeline
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Purchased Database
1.3.3. Internal Database
1.3.4. Secondary Sources
1.3.5. Primary Research
1.4. Information or Data Analysis
1.4.1. Data Analysis Models
1.5. Market Formulation & Validation
1.5.1. Region Wise Market: Base Estimates
1.5.2. Global Market: CAGR Calculation
1.6. Model Details
1.6.1. Commodity Flow Analysis (Model 1)
1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
1.6.3. QFD Model Sizing & Forecasting (Model 3)
1.6.4. Bottom-Up Approach (Model 4)
1.7. List of Secondary Sources
1.8. List of Abbreviations
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Nucleic Acid Therapeutics CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Rising incidence of genetic disorders across the globe
3.2.1.2. Robust expansion of the genomics research sector and strong traction gained by custom oligonucleotides
3.2.1.3. Increasing demand for one-stop-shop CDMOs and growing foreign direct investments in nucleic acid therapeutics
3.2.2. Market Restraint Analysis
3.2.2.1. Limited outsourcing by big pharmaceutical and biopharmaceutical companies
3.2.2.2. Stringent regulatory framework
3.3. Clinical Trials Volume Analysis, 2023
3.3.1. Total Number of Clinical Trials, by Region (2023)
3.3.2. Total Number of Clinical Trials, by Phase (2023)
3.3.3. Total Number of Clinical Trials, by Study Design (2023)
3.3.4. Total Number of Clinical Trials, by Key Therapeutic Area (2023)
3.4. Nucleic Acid Therapeutics CDMO Market: Analysis Tools
3.4.1. Porter’s Five Forces Analysis
3.4.2. PESTEL Analysis
3.5. COVID-19 Impact Analysis
Chapter 4. Nucleic Acid Therapeutics CDMO Market: Type Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Nucleic Acid Therapeutics CDMO Market Movement Analysis
4.3. Global Nucleic Acid Therapeutics CDMO Market Size & Trend Analysis, by Type, 2018 to 2030 (USD Million)
4.4. Gene Therapy
4.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
4.5. RNA-based Therapies
4.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
Chapter 5. Nucleic Acid Therapeutics CDMO Market: Service Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Global Nucleic Acid Therapeutics CDMO Market Movement Analysis
5.3. Global Nucleic Acid Therapeutics CDMO Market Size & Trend Analysis, by Service, 2018 to 2030 (USD Million)
5.4. Process Development and Optimization
5.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
5.5. Manufacturing Services
5.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
5.6. Analytical and Quality Control Services
5.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
Chapter 6. Nucleic Acid Therapeutics CDMO Market: End Use Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Global Nucleic Acid Therapeutics CDMO Market Movement Analysis
6.3. Global Nucleic Acid Therapeutics CDMO Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
6.4. Pharmaceutical Companies
6.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.5. Government & Academic Research Institutes
6.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
6.6. Biotech Companies
6.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
Chapter 7. Nucleic Acid Therapeutics CDMO Market: Application Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Global Nucleic Acid Therapeutics CDMO Market Movement Analysis
7.3. Global Nucleic Acid Therapeutics CDMO Market Size & Trend Analysis, Application, 2018 to 2030 (USD Million)
7.4. Rare Diseases
7.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.5. Genetic Disorders
7.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.6. Infectious Diseases
7.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
7.7. Others
7.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
Chapter 8. Nucleic Acid Therapeutics CDMO Market: Regional Estimates & Trend Analysis
8.1. Regional Market Dashboard
8.2. Global Regional Market Snapshot
8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030
8.4. North America
8.4.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Scenario
8.4.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Scenario
8.4.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.4.4. Mexico
8.4.4.1. Key Country Dynamics
8.4.4.2. Competitive Scenario
8.4.4.3. Regulatory Scenario
8.4.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.5. Europe
8.5.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.5.2. UK
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Scenario
8.5.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.5.3. Germany
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Scenario
8.5.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.5.4. France
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Scenario
8.5.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.5.5. Italy
8.5.5.1. Key Country Dynamics
8.5.5.2. Competitive Scenario
8.5.5.3. Regulatory Scenario
8.5.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.5.6. Spain
8.5.6.1. Key Country Dynamics
8.5.6.2. Competitive Scenario
8.5.6.3. Regulatory Scenario
8.5.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.5.7. Denmark
8.5.7.1. Key Country Dynamics
8.5.7.2. Competitive Scenario
8.5.7.3. Regulatory Scenario
8.5.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.5.8. Sweden
8.5.8.1. Key Country Dynamics
8.5.8.2. Competitive Scenario
8.5.8.3. Regulatory Scenario
8.5.8.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.5.9. Norway
8.5.9.1. Key Country Dynamics
8.5.9.2. Competitive Scenario
8.5.9.3. Regulatory Scenario
8.5.9.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.6. Asia Pacific
8.6.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.6.2. China
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Scenario
8.6.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.6.3. Japan
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Scenario
8.6.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.6.4. India
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Scenario
8.6.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.6.5. Australia
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Regulatory Scenario
8.6.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.6.6. South Korea
8.6.6.1. Key Country Dynamics
8.6.6.2. Competitive Scenario
8.6.6.3. Regulatory Scenario
8.6.6.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.6.7. Thailand
8.6.7.1. Key Country Dynamics
8.6.7.2. Competitive Scenario
8.6.7.3. Regulatory Scenario
8.6.7.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.7. Latin America
8.7.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.7.2. Brazil
8.7.2.1. Key Country Dynamics
8.7.2.2. Competitive Scenario
8.7.2.3. Regulatory Scenario
8.7.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Competitive Scenario
8.7.3.3. Regulatory Scenario
8.7.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.8. MEA
8.8.1. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.8.2. South Africa
8.8.2.1. Key Country Dynamics
8.8.2.2. Competitive Scenario
8.8.2.3. Regulatory Scenario
8.8.2.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.8.3. Saudi Arabia
8.8.3.1. Key Country Dynamics
8.8.3.2. Competitive Scenario
8.8.3.3. Regulatory Scenario
8.8.3.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.8.4. UAE
8.8.4.1. Key Country Dynamics
8.8.4.2. Competitive Scenario
8.8.4.3. Regulatory Scenario
8.8.4.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
8.8.5. Kuwait
8.8.5.1. Key Country Dynamics
8.8.5.2. Competitive Scenario
8.8.5.3. Regulatory Scenario
8.8.5.4. Market Estimates and Forecast, 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
9.1. Market Participant Categorization
9.1.1. Market Leaders
9.1.2. Emerging Players
9.2. Competitive Market share, by Industry (2023)
9.3. Competition Mapping by Service Type (2023)
9.4. Service Heat Map Analysis (a comparative analysis of the players together)
9.5. Company Profiles
9.5.1. Agilent Technologies, Inc
9.5.1.1. Company Overview
9.5.1.2. Financial Performance
9.5.1.3. Service Benchmarking
9.5.1.4. Strategic Initiatives
9.5.2. Curia Global, Inc.
9.5.2.1. Company Overview
9.5.2.2. Financial Performance
9.5.2.3. Service Benchmarking
9.5.2.4. Strategic Initiatives
9.5.3. Ajinomoto Co., Inc.
9.5.3.1. Company Overview
9.5.3.2. Financial Performance
9.5.3.3. Service Benchmarking
9.5.3.4. Strategic Initiatives
9.5.4. Danaher Corporation
9.5.4.1. Company Overview
9.5.4.2. Financial Performance
9.5.4.3. Service Benchmarking
9.5.4.4. Strategic Initiatives
9.5.5. KNC Laboratories Co., Ltd.
9.5.5.1. Company Overview
9.5.5.2. Financial Performance
9.5.5.3. Service Benchmarking
9.5.5.4. Strategic Initiatives
9.5.6. LGC Limited
9.5.6.1. Company Overview
9.5.6.2. Financial Performance
9.5.6.3. Service Benchmarking
9.5.6.4. Strategic Initiatives
9.5.7. Merck KGaA
9.5.7.1. Company Overview
9.5.7.2. Financial Performance
9.5.7.3. Service Benchmarking
9.5.7.4. Strategic Initiatives
9.5.8. WuXi AppTec
9.5.8.1. Company Overview
9.5.8.2. Financial Performance
9.5.8.3. Service Benchmarking
9.5.8.4. Strategic Initiatives
9.5.9. BIOSPRING
9.5.9.1. Company Overview
9.5.9.2. Financial Performance
9.5.9.3. Service Benchmarking
9.5.9.4. Strategic Initiatives
9.5.10. Exothera
9.5.10.1. Company Overview
9.5.10.2. Financial Performance
9.5.10.3. Service Benchmarking
9.5.10.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 Global Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 4 Global Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 5 Global Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 6 Global Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 7 Global Nucleic Acid Therapeutics CDMO, by Region, 2018 - 2030 (USD Million)
Table 8 North America Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
Table 9 North America Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 10 North America Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 11 North America Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 12 North America Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 13 U.S Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 14 U.S Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 15 U.S Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 16 U.S Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 17 Canada Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 18 Canada Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 19 Canada Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 20 Canada Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 21 Mexico Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 22 Mexico Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 23 Mexico Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 24 Mexico Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 25 Europe Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
Table 26 Europe Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 27 Europe Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 28 Europe Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 29 Europe Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 30 Germany Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 31 Germany Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 32 Germany Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 33 Germany Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 34 UK Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 35 UK Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 36 UK Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 37 UK Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 38 France Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 39 France Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 40 France Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 41 France Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 42 Italy Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 43 Italy Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 44 Italy Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 45 Italy Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 46 Spain Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 47 Spain Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 48 Spain Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 49 Spain Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 50 Denmark Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 51 Denmark Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 52 Denmark Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 53 Denmark Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 54 Sweden Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 55 Sweden Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 56 Sweden Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 57 Sweden Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 58 Norway Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 59 Norway Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 60 Norway Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 61 Norway Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 62 Asia Pacific Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
Table 63 Asia Pacific Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 64 Asia Pacific Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 65 Asia Pacific Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 66 Asia Pacific Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 67 China Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 68 China Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 69 China Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 70 China Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 71 Japan Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 72 Japan Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 73 Japan Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 74 Japan Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 75 India Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 76 India Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 77 India Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 78 India Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 79 South Korea Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 80 South Korea Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 81 South Korea Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 82 South Korea Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 83 Australia Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 84 Australia Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 85 Australia Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 86 Australia Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 87 Thailand Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 88 Thailand Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 89 Thailand Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 90 Thailand Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 91 Latin America Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
Table 92 Latin America Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 93 Latin America Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 94 Latin America Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 95 Latin America Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 96 Brazil Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 97 Brazil Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 98 Brazil Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 99 Brazil Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 100 Argentina Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 101 Argentina Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 102 Argentina Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 103 Argentina Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 104 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Country, 2018 - 2030 (USD Million)
Table 105 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 106 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 107 Middle East & Africa Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 108 Middle East & Africa Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 109 South Africa Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 110 South Africa Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 111 South Africa Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 112 South Africa Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 113 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 114 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 115 Saudi Arabia Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 116 Saudi Arabia Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 117 UAE Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 118 UAE Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 119 UAE Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 120 UAE Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
Table 121 Kuwait Nucleic Acid Therapeutics CDMO, by Type, 2018 - 2030 (USD Million)
Table 122 Kuwait Nucleic Acid Therapeutics CDMO, by Service, 2018 - 2030 (USD Million)
Table 123 Kuwait Nucleic Acid Therapeutics CDMO, by End Use, 2018 - 2030 (USD Million)
Table 124 Kuwait Nucleic Acid Therapeutics CDMO, by Application, 2018 - 2030 (USD Million)
List of Figures
Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 Nucleic Acid Therapeutics CDMO Market Segmentation
Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 10 Porter’s Five Forces Analysis
Fig. 11 Regional Marketplace: Key Takeaways
Fig. 12 Global Nucleic Acid Therapeutics CDMO, for Gene Therapy, 2018 - 2030 (USD Million)
Fig. 13 Global Nucleic Acid Therapeutics CDMO, for RNA-based Therapies, 2018 - 2030 (USD Million)
Fig. 14 Global Nucleic Acid Therapeutics CDMO, for Process Development and Optimization, 2018 - 2030 (USD Million)
Fig. 15 Global Nucleic Acid Therapeutics CDMO, for Manufacturing Services, 2018 - 2030 (USD Million)
Fig. 16 Global Nucleic Acid Therapeutics CDMO, for Analytical and Quality Control Services, 2018 - 2030 (USD Million)
Fig. 17 Global Nucleic Acid Therapeutics CDMO, for Others, 2018 - 2030 (USD Million)
Fig. 18 Global Nucleic Acid Therapeutics CDMO, for Pharmaceutical Companies, 2018 - 2030 (USD Million)
Fig. 19 Global Nucleic Acid Therapeutics CDMO, for Government & Academic Research Institutes, 2018 - 2030 (USD Million)
Fig. 20 Global Nucleic Acid Therapeutics CDMO, for Biotech Companies, 2018 - 2030 (USD Million)
Fig. 21 Global Nucleic Acid Therapeutics CDMO, for Rare Diseases, 2018 - 2030 (USD Million)
Fig. 22 Global Nucleic Acid Therapeutics CDMO, for Genetic Disorders, 2018 - 2030 (USD Million)
Fig. 23 Global Nucleic Acid Therapeutics CDMO, for Infectious Diseases, 2018 - 2030 (USD Million)
Fig. 24 Global Nucleic Acid Therapeutics CDMO, for Others, 2018 - 2030 (USD Million)
Fig. 25 Regional Outlook, 2023 & 2030
Fig. 26 North America Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 27 U.S. Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 28 Canada Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 29 Mexico Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 30 Europe Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 31 Germany Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 32 UK Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 33 France Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 34 Italy Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 35 Spain Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 36 Denmark Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 37 Sweden Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 38 Norway Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 39 Asia Pacific Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 40 Japan Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 41 China Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 42 India Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 43 Australia Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 44 South Korea Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 45 Thailand Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 46 Latin America Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 47 Brazil Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 48 Argentina Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 49 Middle East and Africa Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 50 South Africa Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 51 Saudi Arabia Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 52 UAE Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Fig. 53 Kuwait Nucleic Acid Therapeutics CDMO Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Companies Mentioned

  • Agilent Technologies, Inc.
  • Curia Global, Inc.
  • Ajinomoto Co., Inc.
  • Danaher (Aldevron)
  • KNC Laboratories Co., Ltd.
  • LGC Limited
  • Merck KGaA
  • WuXi AppTec
  • BIOSPRING
  • Univercells Inc.
  • Exothera

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages125
PublishedAugust 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 13.53 Billion
Forecasted Market Value ( USD ) by 2030 $ 33.86 Billion
Compound Annual Growth Rate14.1%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Nucleic Acid Therapeutics CDMO Market by Type, Service, Application, End-user - Global Forecast 2025-2030 - Product Image

Nucleic Acid Therapeutics CDMO Market by Type, Service, Application, End-user - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Nucleic Acid Therapeutics CDMO Market - Product Image

Nucleic Acid Therapeutics CDMO Market

  • Report
  • 200 Pages
  • Global
From
Nucleic Acid Therapeutics CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Nucleic Acid Therapeutics CDMO Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 184 Pages
  • Global
From
Peptide And Oligonucleotide CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029) - Product Image

Peptide And Oligonucleotide CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

  • Report
  • 120 Pages
  • Global
From
Recombinant Protein Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Growth Hormones, Interferons, Vaccines, Immunostimulating Agents, Others), By Source, By Indication, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Recombinant Protein Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type (Growth Hormones, Interferons, Vaccines, Immunostimulating Agents, Others), By Source, By Indication, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 173 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.